|
|
|
Serum Occludin as a Biomarker to Predict the Severity of Acute Ischemic Stroke, Hemorrhagic Transformation, and Patient Prognosis
|
|
Li Weili, Qi Zhifeng, Kang Huining, Qin Xuzhen, Song Haiqing, Sui Xueqin, Ren Yi, Ji Xunming, Ma Qingfeng, Jian Liu Ke
|
|
| |
| Table 4 Analysis of prognostic risk factors for CI with non-reperfusion therapy. |
|
| Variable | mRS=0-2
(n=59) | mRS≥3
(n=26) | P values |
|---|
| Age — yr | 66.46±13.34 | 68.32±14.76 | 0.570 | | Male sex — no. (%) | 43 (72.9) | 17 (65.4) | 0.284 | | Atrial fibrillation — no. (%) | 4 (6.8) | 7 (26.9) | 0.028 | | Diabetes mellitus — no. (%) | 13 (22.0) | 4 (15.4) | 0.680 | | Hypertension — no. (%) | 25 (42.4) | 15 (57.7) | 0.192 | | Median NIHSS score (IQR) | 2 (1-4) | 12 (10-14) | 0.000 | | Previous stroke — no. (%) | 10 (9.3) | 7 (12.7) | 0.493 | | Median Onset to Door time— hr. (IQR) | 5 (2.5-12) | 5.75 (4.5-9.75) | 0.509 | | Serum occludin levels (ng/mL) | 3.93±1.16 | 5.11±1.48 | <0.001 | | LDL-C (mmol/L) | 2.77±1.02 | 3.06±0.97 | 0.266 | | HDL-C (mmol/L) | 1.27±0.37 | 1.23±0.35 | 0.683 | | TG (mmol/L) | 1.79±1.10 | 1.77±0.86 | 0.938 | | GLU (mmol/L) | 7.58±3.74 | 7.61±3.18 | 0.969 | | FIB (g/L) | 3.61±0.80 | 4.30±1.27 | 0.007 | | WBC (109/L) | 7.28±2.18 | 9.01±1.96 | 0.002 | | NEUT (%) | 63.43±11.42 | 74.51±13.98 | 0.001 |
|
|
|